Literature DB >> 10696963

The role of pretreatment squamous cell carcinoma antigen in predicting nodal metastasis in early stage cervical cancer.

H Lin1, C C ChangChien, E Y Huang, C W Tseng, H L Eng, C C Huang.   

Abstract

PURPOSE: To evaluate whether the presence of pelvic lymph node metastasis can be predicted by pretreatment squamous cell carcinoma antigen (SCC-Ag) levels in early stage squamous cervical carcinoma.
MATERIALS AND METHODS: Between 1994 and 1998, 284 patients with stage Ib and IIa cervical squamous cell carcinoma undergoing radical hysterectomy had preoperative SCC-Ag determination. The correlation between clinicopathological findings on SCC-Ag levels were examined. The Mann-Whitney U test was used to statistically analyze differences between node positive and negative patients. Multiple regression analysis and a multiple logistic model were employed to examine the effect of clinicopathological findings on SCC-Ag levels.
RESULTS: Of the 284 patients, 56 patients were found to have nodal metastasis. Median serum levels and 90% ranges of SCC-Ag were 0.74 microg/l (0.5-7.8) in the 228 nodal negative patients and 4.33 microg/l (0.5-48.5) in the 56 nodal positive patients (p<0.001). Lymph node metastasis and tumor size were found to have a significant impact on SCC-Ag levels. Around 86% of the patients with SCC-Ag levels below 8 microg/l showed no nodal metastasis, while about 65% of the patients with serum levels above 8 microg/l exhibited nodal metastasis. Multivariate analyses confirmed that only lymph node metastasis had a significant impact on the SCC-Ag levels exceeding 8 microg/l.
CONCLUSION: For predicting nodal metastasis preoperatively, SCC-Ag levels greater than 8 microg/ l can be considered a high-risk zone for nodal metastasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696963     DOI: 10.1034/j.1600-0412.2000.079002140.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  CISD2 expression is a novel marker correlating with pelvic lymph node metastasis and prognosis in patients with early-stage cervical cancer.

Authors:  Luxin Liu; Meng Xia; Jing Wang; Weijing Zhang; Yanna Zhang; Mian He
Journal:  Med Oncol       Date:  2014-08-20       Impact factor: 3.064

2.  Predictive value of preoperative serum squamous cell carcinoma antigen level for lymph node metastasis in early-stage cervical squamous cell carcinoma.

Authors:  Chenggong Zhu; Wenqing Zhang; Xiuying Wang; Lanzhou Jiao; Liyan Chen; Jiyong Jiang
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

3.  The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.

Authors:  Xiong Li; Jin Zhou; Kecheng Huang; Fangxu Tang; Hang Zhou; Shaoshuai Wang; Yao Jia; Haiying Sun; Ding Ma; Shuang Li
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

Review 4.  The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review.

Authors:  Ziqi Zhou; Wenbo Li; Fuquan Zhang; Ke Hu
Journal:  PLoS One       Date:  2017-12-11       Impact factor: 3.240

5.  Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors.

Authors:  Hong-Tao Guo; Xue-Han Bi; Ting Lei; Xiao Lv; Guang Yao; Yao Chen; Chang Liu
Journal:  BMC Cancer       Date:  2020-05-19       Impact factor: 4.430

6.  Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.

Authors:  Stephanie Markovina; Songyan Wang; Lauren E Henke; Cliff J Luke; Stephen C Pak; Todd DeWees; John D Pfeifer; Julie K Schwarz; Weijun Liu; Shuai Chen; David Mutch; Xiaowei Wang; Matthew A Powell; Barry A Siegel; Farrokh Dehdashti; Gary A Silverman; Perry W Grigsby
Journal:  Br J Cancer       Date:  2017-11-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.